PWMG
STOK icon

Provence Wealth Management Group’s Stoke Therapeutics STOK Stock Holding History

Provence Wealth Management Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$2.47K Hold
470
– – ﹤0.01% 390
2023
Q3 		$1.85K Buy
+470
New +$3.09K ﹤0.01% 404

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Provence Wealth Management Group's STOK Position: Q4 2023 in Review

Provence Wealth Management Group held its Stoke Therapeutics (STOK) position steady in Q4 2023 at 470 shares worth $2.47K. The position accounts for ﹤0.01% of the portfolio, ranked #390.

Provence Wealth Management Group first reported a position in STOK in Q3 2023 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold STOK as of Q4 2023.

  • Provence Wealth Management Group held 470 shares of Stoke Therapeutics worth $2.47K as of Q4 2023.
  • Provence Wealth Management Group left its Stoke Therapeutics share count unchanged in Q4 2023.
  • Stoke Therapeutics made up ﹤0.01% of Provence Wealth Management Group's portfolio in Q4 2023, its #390 holding.
  • Provence Wealth Management Group first reported a position in Stoke Therapeutics in Q3 2023 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2023.

Based on Provence Wealth Management Group's 13F filing for Q4 2023, filed 6 Feb 2024.